First United Bank Trust decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 7.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,483 shares of the medical instruments supplier’s stock after selling 512 shares during the quarter. First United Bank Trust’s holdings in Becton Dickinson and were worth $1,640,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in BDX. InterOcean Capital LLC acquired a new position in shares of Becton Dickinson and during the 1st quarter worth $204,000. Northeast Financial Consultants Inc acquired a new position in shares of Becton Dickinson and during the 1st quarter worth $200,000. American Century Companies Inc. grew its stake in Becton Dickinson and by 2.0% in the 1st quarter. American Century Companies Inc. now owns 1,187,439 shares of the medical instruments supplier’s stock valued at $296,539,000 after buying an additional 23,118 shares during the last quarter. GQG Partners LLC grew its stake in Becton Dickinson and by 13.1% in the 1st quarter. GQG Partners LLC now owns 867,097 shares of the medical instruments supplier’s stock valued at $215,908,000 after buying an additional 100,558 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Becton Dickinson and by 1.0% in the 1st quarter. Fifth Third Bancorp now owns 38,772 shares of the medical instruments supplier’s stock valued at $9,683,000 after buying an additional 370 shares during the last quarter. Institutional investors own 84.21% of the company’s stock.
NYSE:BDX opened at $252.86 on Friday. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74. The firm’s fifty day simple moving average is $253.69 and its 200 day simple moving average is $245.85. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $66.90 billion, a PE ratio of 22.97, a PEG ratio of 1.58 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the business posted $2.91 EPS. Becton Dickinson and’s revenue was up 1.7% compared to the same quarter last year. As a group, analysts anticipate that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date was Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.
In other Becton Dickinson and news, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the completion of the sale, the executive vice president now directly owns 16,535 shares of the company’s stock, valued at approximately $4,217,417.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the sale, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 37,249 shares of company stock valued at $9,616,803. Insiders own 0.12% of the company’s stock.
A number of research analysts recently issued reports on BDX shares. Piper Jaffray Companies lowered their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co raised their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Finally, Raymond James raised their target price on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $266.55.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: How are institutional investors different from individual investors?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.